Chemistry:Incyclinide
 | |
| Clinical data | |
|---|---|
| Trade names | Metastat (proposed) |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H17NO7 |
| Molar mass | 371.345 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Incyclinide (proposed trade name Metastat) is a chemically modified tetracycline antibiotic that was investigated in clinical trials for the treatment of rosacea,[1] various tumours, allergic and inflammatory diseases and a number of other conditions.[2][3]
Data from animal studies suggest that centrally infused incyclinide attenuates microglial mediated neuroinflammation in the paraventricular nucleus of the hypothalamus and sympathetic activation in angiotensin II-induced hypertension. This was also associated with unique changes in gut microbial communities and profound attenuation of gut pathology in animal models of hypertension.[4]
Mechanism of action
Like other tetracyclines, incyclinide inhibits matrix metalloproteinases. In contrast to traditional tetracyclines, it lacks antibiotic properties.[5]
References
- ↑ Reuters: CollaGenex says incyclinide ineffective for rosacea
- ↑ "Neue Wirkstoffe - Incyclinid" (in German). Österreichische Apothekerzeitung (14/2007): 655. 2 July 2007.
- ↑ ClinicalTrials.gov: Incyclinide
- ↑ "Microglial Cells Impact Gut Microbiota and Gut Pathology in Angiotensin II-Induced Hypertension". Circulation Research 124 (5): 727–736. March 2019. doi:10.1161/CIRCRESAHA.118.313882. PMID 30612527.
- ↑ "Incyclinide". Drugs of the Future 32 (3): 209–214. 2007. doi:10.1358/dof.2007.032.03.1083308. http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1083308&p_IsPs=N.
 |  |
